AstraZeneca Pharmaceuticals LP (manufacturer of the medicinal product "in bulk")

The drug is prescribed to women in postmenopause for adjuvant treatment of hormone receptor-positive invasive breast cancer (both in early stages and after tamoxifen therapy), as well as for the treatment of advanced hormone receptor-positive breast cancer.

Dosage form: tablets, film-coated

ATC: L02BG03